Key takeaways
- Pick shows by who is in the room, not by attendance figures: a smaller function-specific show can beat a larger flagship if your exact buyer is concentrated there.
- For CROs, SCOPE Summit and DIA are tightly targeted options; scientific congresses like ASCO, ASH, AACR, and SITC work as therapeutic-area plays.
- For CDMOs, DCAT Week, CPHI, and ISPE are useful anchor candidates, with modality-specific manufacturing shows for cell and gene therapy specialists.
- BIO and JPM Healthcare Week are shared, partnering-first venues: valuable for relationships and deal flow rather than direct near-term pipeline.
Many lists of "best life science conferences" rank shows by size. For business development, that is only a proxy. A CRO's buyer is clinical development leadership; a CDMO's buyer sits in sourcing, supply chain, and manufacturing. The best show for your team is the one where that specific buyer is concentrated, and by that measure the answer looks quite different for the two personas, and quite different from the generic listicles.
How should a services company judge a conference?
By one question: is the person who selects vendors like you concentrated in this room? Attendance figures, exhibit-hall size, and press coverage are all proxies, because flagship shows draw many people who have nothing to do with your sale. A function-specific show a fraction of the size can still be more useful if it concentrates your real buyers. That is why the honest answer to "what are the best shows" is a persona-filtered one, and why the two lists below only partly overlap. Dates, locations, and detail for the linked US events are on the US life science conference calendar; verify international events on their official sites.
Which conferences are best for CRO business development?
For a CRO, the buyer is clinical operations and development leadership inside sponsor companies, and the calendar sorts into three tiers around that fact:
- SCOPE Summit is a tightly targeted room for CRO selling: the audience is clinical operations leadership specifically, the people who run trials and select CROs, rather than a general biotech crowd.
- DIA Global Annual Meeting reaches the regulatory and clinical development audience in depth, a strong fit for CROs whose story leans on regulatory strategy, data management, or full-service development.
- The big scientific congresses, ASCO for oncology, ASH for hematology, AACR for cancer research, and SITC for immuno-oncology, work as therapeutic-area plays: the audience is scientific rather than procurement, but for a CRO focused on those areas, sponsors and investigators behind relevant programs may be present, and the presentations can show which programs are moving.
- BIO International is the broad relationship-and-partnering venue: useful for early relationship building and staying visible to the market, often with a lower direct-pipeline hit rate than the function-specific shows above.
Which conferences are best for CDMO business development?
A CDMO's buyer rarely walks the clinical shows. The center of gravity is the sourcing, supply chain, and manufacturing circuit:
- DCAT Week is close to home turf for many CDMO teams: a week built around private business meetings rather than a show floor, with access and meeting value dependent on DCAT membership, invitations, and preparation before the week starts.
- CPHI and ISPE round out the core circuit: CPHI Americas for the broad pharma sourcing and supply audience in the region, CPHI Milan for the global flagship in Italy, and ISPE for pharmaceutical engineering and manufacturing operations.
- Modality-specific manufacturing shows, BPI West, Biotech Week Boston, and Phacilitate Advanced Therapies Week for cell and gene therapy, can reach the modality and scale-stage audience a specialized CDMO needs, and INTERPHEX serves the broader manufacturing-technology crowd.
- Partnering venues, BIO and JPM Healthcare Week, matter for a CDMO too, less for lead generation than because manufacturing partnerships increasingly get shaped in the same rooms where licensing and financing conversations happen.
Which shows do both personas share?
BIO International and JPM Healthcare Week, and the honest framing for both is the same: they are partnering and relationship venues, not direct pipeline machines. The value is meeting density, the number of decision-makers reachable in a few days, rather than room composition. Both reward heavy pre-booking through partnering systems and planned meetings, and both tend to underperform for teams who show up hoping the floor will provide.
How do you turn a show list into a working calendar?
Three moves. First, anchor on the one or two function-specific shows where your buyer actually concentrates, SCOPE or DIA for a CRO, DCAT Week or CPHI for a CDMO, and give those shows real preparation: a target list built from the exhibitor and speaker lists weeks ahead, and meetings booked before the show opens. Second, add one partnering flagship for relationships and market presence. Third, layer in the niche or therapeutic-area shows that match your specific focus, where a smaller room may be the more relevant room. The mechanics of working each show, before, during, and after, are covered in selling around life science conferences and how to turn a conference into pipeline.